FGFR3 Y373C
|
Urothelial Cancer
|
FGFR3 Y373C
|
Urothelial Cancer
|
infigratinib Sensitive: C3 – Early Trials
|
infigratinib Sensitive: C3 – Early Trials
|
FGFR3 Y373C
|
Urothelial Cancer
|
FGFR3 Y373C
|
Urothelial Cancer
|
erdafitinib Sensitive: C3 – Early Trials
|
erdafitinib Sensitive: C3 – Early Trials
|
FGFR3 Y373C
|
Urothelial Cancer
|
FGFR3 Y373C
|
Urothelial Cancer
|
FGFR2 inhibitor Resistant: C3 – Early Trials
|
FGFR2 inhibitor Resistant: C3 – Early Trials
|
FGFR3 Y373C
|
Urothelial Cancer
|
FGFR3 Y373C
|
Urothelial Cancer
|
FGFR3 inhibitor Resistant: C3 – Early Trials
|
FGFR3 inhibitor Resistant: C3 – Early Trials
|
FGFR3 Y373C
|
Multiple Myeloma
|
FGFR3 Y373C
|
Multiple Myeloma
|
TAS 120 Sensitive: D – Preclinical
|
TAS 120 Sensitive: D – Preclinical
|
FGFR3 Y373C
|
Multiple Myeloma
|
FGFR3 Y373C
|
Multiple Myeloma
|
bortezomib Resistant: D – Preclinical
|
bortezomib Resistant: D – Preclinical
|